Trial Profile
A Phase 1 Multicenter, Open-label, Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Antitumor Activity of MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Jun 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tavolimab (Primary) ; Tremelimumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors MedImmune
- 14 Jun 2022 Results (n=31) assessing safety and tolerability published in the Clinical Cancer Research
- 31 May 2020 Results of safety and tolerability, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 22 Aug 2019 Status changed from active, no longer recruiting to completed.